Search PubMed⌕ Search

Biomedical subjects

N Williams

Publications and source records attributed to N Williams.

At least 289 records · Page 16Linked to original sources

The mitochondrial ATP synthase of Trypanosoma brucei: developmental regulation through the life cycle.

The mitochondrial H(+)-ATPase of the parasitic protozoan Trypanosoma brucei is shown to be developmentally regulated through the T. brucei life cycle as has been shown for components of the mitochondrial electron transport chain. We have substantiated our results by assaying not only for oligomycin-sensitive ATPase activity but also by determining the level of ATP synthetic activity. These results show that the level of ATPase present in the procyclic form of T. brucei is increased by at least threefold from that of the early bloodstream form while the ATPase activity in the late bloodstream form is only about twofold higher than the early form. ATP synthesis activity shows these same results. We have determined the level of ATP synthase protein present in the life cycle stages by Western analysis employing the antibodies that we have raised against both the water soluble F1 and the membrane-associated F0 moieties which we have purified from T. brucei. The Western blots of the procyclic form show strong reactivity with both the F0 and F1 antibodies. The other two life cycle stages, the early and the late bloodstream forms, show considerably less reactivity, paralleling the activity results. Electron micrographs of the sonicated mitochondrial fraction show inverted vesicles which are studded with knobby H(+)-ATPase in the procyclic form. The early bloodstream vesicles show very few of these characteristic structures, while the late bloodstream form shows a range of vesicles from nearly nude to partially studded.

Adenosine Triphosphatases↗

Raf-1 is a potential substrate for mitogen-activated protein kinase in vivo.

MAP (mitogen-activated protein) kinase is shown to phosphorylate baculovirally expressed Raf-1 in vitro, generating one major tryptic phosphopeptide which co-migrated with a peptide from Raf-1 32P-labelled in situ. This peptide also undergoes an insulin-dependent increase in labelling. Thus the serine/threonine kinase Raf-1 may be a substrate for MAP kinase in vivo.

Animals↗

Is thrombopoietin interleukin 6?

Recent data concerning to ability of interleukin 6 (IL-6) to stimulate platelet production have raised the possibility that platelet production is not specifically regulated by a unique feedback mechanism, but is part of a network encompassing several hemopoietic growth factors. Hypotheses are presented about the nature of thrombopoietin, its relationship to known growth factors, especially IL-6, and the specificity of a thrombopoietic response following change in the circulating platelet mass.

Growth Substances↗

Compensatory mechanisms in platelet production: the response of Sl/Sld mice to 5-fluorouracil.

Sl/Sld mice are a unique animal model for studying platelet production in that they sustain normal platelet mass despite reduced marrow activity. The aim of this study was to determine if the compensatory mechanisms operating in these mice could be augmented by further reducing bone marrow activity with the drug 5-fluorouracil (5-FU), known to induce a strong stimulatory effect on platelet production. The platelet recovery in Sl/Sld mice after 5-FU administration contrasted that found in their normal littermates. Sl/Sld mice did not display the sustained thrombocytosis that was observed in +/+ mice between days 10 and 14. Platelet number was elevated in Sl/Sld mice at day 20, when the marrow megakaryocyte compartment had normalized. A significant increase in marrow megakaryocyte number and size was observed at days 8 and 11 in both +/+ and Sl/Sld mice after 5-FU administration. The data suggest that the increase in megakaryocyte size and number following 5-FU treatment was not able to significantly contribute to a sustained rebound thrombocytosis at the time of increased marrow megakaryocytopoiesis. It is concluded that the already compromised marrow of Sl/Sld mice is able to respond to the damage invoked by 5-FU to produce larger than normal megakaryocytes. In contrast to normal mice (+/+ littermates), the increase in marrow megakaryocytopoiesis observed does not lead to a thrombocytosis, indicating that platelet production and release in Sl/Sld mice cannot be further amplified by a strong marrow stimulation.

Anemia↗

Tumor immunization. Improved results after vaccine modified with recombinant interferon gamma.

The purpose of this study was to determine if a 3-day in vitro culture of the murine neuroblastoma C1300 with 500 U/mL of recombinant interferon gamma resulted in a protective crossreactivity to parent C1300. Twenty A/J mice received either a vaccine of 1 x 10(6) irradiated C1300 tumor cells intradermally or an equivalent inoculum of C1300 that had been incubated in recombinant interferon gamma (C1300*). One week later, all animals were rechallenged with 1 x 10(6) viable C1300. Animals immunized with C1300* had a significantly delayed early tumor incidence that translated into a survival advantage for the group. At the time of tumor rechallenge, a significantly increased level of nonspecific systemic immunity was conferred by the C1300* immunization. Thus, modification of tumor with recombinant interferon gamma before introduction as a vaccine may improve that vaccine's protective capability.

Animals↗

Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha.

Carcinoma cells frequently coexpress transforming growth factor (TGF)-alpha and its receptor, the epidermal growth factor (EGF) receptor, implicating an autocrine function of carcinoma-derived TGF-alpha. Using a monoclonal antibody (425) to the EGF-receptor, we investigated the role of exogenous and tumor cell-derived EGF/TGF-alpha mitogenic activities in proliferation of cell lines derived from solid tumors. Monoclonal antibody 425 was chosen for these studies because it inhibits binding of EGF/TGF-alpha to the EGF-receptor and effectively blocks activation of the EGF-receptor by EGF/TGF-alpha. Seven malignant cell lines originating from carcinomas of colon, pancreas, breast, squamous epithelia, and bladder expressed surface EGF-receptor and secreted EGF/TGF-alpha-like mitogenic activities into their tissue culture media. All cell lines were maintained in a defined medium free of exogenous EGF/TGF-alpha. EGF and TGF-alpha added to the culture medium stimulated proliferation of five cell lines to comparable levels. EGF/TGF-alpha-dependent proliferation was significantly reduced by addition of MAb 425 to culture media. In addition, monoclonal antibody 425 reduced proliferation of the five EGF/TGF-alpha responsive cell lines in the absence of exogenous EGF/TGF-alpha. Antiproliferative effects induced by monoclonal antibody 425 were reversible and could be overcome by addition of EGF to culture media. Our results indicate that tumor-derived EGF-receptor-reactive mitogens can promote proliferation of carcinoma cells in an autocrine fashion.

Antibodies, Monoclonal↗

The mitochondrial ATP synthase of Trypanosoma brucei: isolation and characterization of the intact F1 moiety.

This report describes the first isolation and molecular characterization of the mitochondrial F1-ATPase from Trypanosoma brucei. The isolation procedure utilized is a modified chloroform extraction procedure. In contrast to earlier reports on the F1-ATPase from other trypanosomatids, the F1-ATPase we have isolated from the procyclic form of T. brucei a complex composed of five distinct subunits. Apparent molecular weights of these subunits are 55,000 [alpha], 42,000 [beta], 32,000 [gamma], 22,000 [delta], and 17,000 [epsilon]. The F1 moiety which possesses the active site of the H(+)-ATPase has an ATPase activity in the standard Tris-HCl coupled enzyme assay with a Vmax of 22.96 mumol min-1 (mg protein)-1 and a Km value of 0.60 mM. This ATPase activity is cold labile and is not susceptible to oligomycin inhibition as is the membrane bound enzyme. Upon reconstitution with F1-ATPase depleted membranes (urea particles) the ATPase regains oligomycin sensitivity to the same extent as that found in the intact inner membrane vesicles. ATP synthesis is also restored to these particles upon reconstitution with F1. These results indicate that this F1-ATPase as isolated is intact with respect to all the critical H(+)-ATPase functions.

Animals↗

Functional expression of Shaker K+ channels in a baculovirus-infected insect cell line.

We constructed a recombinant baculovirus, A. californica nuclear polyhedrosis virus, containing the Drosophila Shaker H4 K+ channel cDNA under control of the polyhedrin promoter. When infected with this recombinant baculovirus, the cell line Sf9, derived from the army-worm caterpillar S. frugiperda, expresses fully functional Shaker transient K+ currents, as assayed by whole-cell recording. K+ currents begin to appear at about 15 hr after infection, and they continue to increase over the next 3 days. Over the same period of time, a 75 kd band appears on SDS gels stained with Coomassie blue. The identity of this band as a Shaker gene product is confirmed by Western blot analysis using an anti-Shaker antiserum. The 75 kd band accounts for a substantial fraction of the membrane protein in Shaker-infected Sf9 cells. These results give hope that the baculovirus system, which has been used successfully for high-level expression of soluble proteins from higher eukaryotes, may be appropriate for producing large amounts of cloned ion channel proteins as well.

Animals↗

Cognitive function in adult epileptic patients established on anticonvulsant monotherapy.

A battery of psychometric tests was administered to 110 patients with epilepsy and to 24 non-epileptic controls. Eighty-four patients had been established on treatment with a single anticonvulsant drug (35 carbamazepine (CBZ), 30 sodium valproate (VPA), 19 phenytoin (PHT)) at unaltered dosage for the previous 3 months. The remaining 26 patients were untreated at the time of study. No individual test discriminated between the groups. Tests were converted to standard scores and summated to give overall psychomotor, memory and side-effect assessments. There were no important differences between the performances of untreated epileptic patients and non-epileptic controls. The CBZ-treated patients had poorer psychomotor scores than both control groups and the VPA-treated patients (all P less than 0.05). The PHT patients scored less well on the composite memory scale than did VPA patients and non-epileptic controls (both P less than 0.05). There were no significant differences in subjective side-effects among the groups. This study demonstrated that anticonvulsant monotherapy has little effect on overall cognitive function in patients tolerating treatment. Psychomotor performance appeared to be selectively influenced by CBZ and memory impaired by PHT. VPA may be the drug to chose when cognitive function is an important consideration. Different cognitive modalities can be affected by different first-line anticonvulsants and this should be taken into account when choosing the most appropriate drug for an individual patient.

Adolescent↗

Stimulators of megakaryocyte development and platelet production.

The range of known purified and cloned growth factors and their target cells within the megakaryocytic lineage is described. Data are reviewed outlining that megakaryocytopoiesis appears to be controlled at two levels: (i) by feedback control via circulating factors, and (ii) by factors within the marrow itself. Hypotheses are presented about the nature of thrombopoietin, its relationship to known growth factors, especially Interleukin-6 (IL-6), and the specificity of a thrombopoietic response following change in the circulating platelet mass.

Animals↗

Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro.

Normal human cells, cells from nonmalignant proliferative lesions, and primary and metastatic tumor cells can be maintained in vitro and analyzed for requirements for growth in chemically defined media. The human melanocytic cell system with normal melanocytes, precursor nevus cells, and primary and metastatic melanoma cells has been extensively studied for the phenotypic properties of the cells, including their requirements for exogenous growth factors and other mitogens. In high calcium-containing W489 medium, normal melanocytes require four supplements: IGF-I (or insulin); bFGF, TPA, and alpha-MSH. Nevus cells are largely independent of bFGF. Depletion of TPA from medium is not as detrimental to nevus cells as it is to melanocytes, but the phorbol ester is still essential for maintenance of the typical nevic phenotype. Primary melanoma cells require at least one growth factor, IGF-I (or insulin), for continuous proliferation. On the other hand, metastatic cells of melanoma as well as of carcinomas of colon and rectum, bladder, ovary, and cervix are able to proliferate after a short adaptation period in medium depleted of any growth factors and other proteins. Doubling times of metastatic tumor cells in protein-free medium are only 30-60% longer than in FCS-containing medium. The growth autonomy of human tumor cells is apparently due to the endogenous production of growth factors. Likely candidates for autocrine growth stimulation of human tumor cells are TGF-alpha, TGF-beta, and PDGF. Melanoma and colorectal carcinoma cells express functional EGF/TGF-alpha receptors, and produce TGF-alpha, indicating that this growth factor is produced for autocrine stimulation. In addition to the use of anti-growth factor antibodies, other strategies for the inhibition of autocrine growth stimulation include mAbs to growth factor receptors, soluble receptors, receptor-mimicking antiidiotype antibodies, and active immunization against growth factors. Whether any of these therapeutic approaches is clinically feasible will need to be determined in extensive preclinical investigations.

Growth Substances↗

Tissue sources of murine megakaryocyte potentiator: biochemical and immunological studies.

The immunological and biochemical characteristics of murine megakaryocyte potentiator from lung and bone marrow were examined and compared with thrombopoietic stimulatory factor. Biological activity was not neutralized by anti-erythropoietin, but megakaryocyte potentiator activity from all three sources was abolished or reduced when the preparations were treated with anti-thrombopoietic stimulatory factor or anti-interleukin-6. Megakaryocyte potentiator levels in lung conditioned medium were not found to be enhanced from mice treated with lipopolysaccharide, in contrast to granulocyte-macrophage colony-stimulating factor (GM-CSF) levels. The biochemical properties of murine megakaryocyte potentiator from lung and bone marrow were compared and found to be similar in the elution profiles from anion exchange, gel filtration and reversed phase liquid chromatography. It is concluded that the activities in lung and bone marrow are very similar if not identical, to interleukin-6.

Animals↗

Megakaryocyte growth factors.

A substantial body of data now indicate that megakaryocytopoiesis is regulated, like erythropoiesis, on at least two levels--a constitutive maintenance of progenitor cells and a megakaryocyte pool that respond to thrombopoietic stimuli in response to altered platelet demand. The above model is assembled on the following observations: (a) Megakaryocyte progenitors are not regulated by platelet mass and therefore are not controlled via thrombopoietin, (b) IL-3 is the most potent stimulator of megakaryocyte progenitor cells described thus far, and therefore is a likely candidate for in-vivo maintenance of progenitor cell numbers, (c) thrombopoietin is the major stimulus for megakaryocyte development into platelets with their subsequent release into the circulation. Can such a model meet physiological requirements? It is not clear that IL-3 can be produced in the bone marrow. At best it can be speculated that megakaryocyte progenitors are sustained by an "IL-3-like" or GM-CSF mechanism but the triggering mechanism may be membrane bound or via a separate molecule that activates a similar mechanism. It is quite possible that IL-3 has little to do with normal megakaryocytopoiesis, and that IL-3 levels are elevated only in immune responses that stimulate T cells to release IL-3. It is now known that IL-3 will stimulate all levels of megakaryocyte development, and this system may be a thrombopoietin-independent nonspecific mechanism of platelet formation. Such a concept demands that IL-3 can stimulate platelet release in the in-vivo thrombopoietin assay, as should appropriate stimulation in vivo by a strong and specific T-cell mitogen. A second hypothesis is that IL-3 may be involved in a synergistic pathway with either TSF or thrombopoietin, based on the synergy between these two types of activities in cell culture. This concept requires that IL-3 be produced in very low but active amounts in the bone marrow or by an IL-3-like mechanism. Amplification of the IL-3-type-induced signal would then depend on the second factor. This mode requires only low levels of IL-3 (may be sub-threshold by Northern blot analysis or biological assays). Synergy with thrombopoietin with IL-3 or an IL-3-like mechanism would mean that only low levels of thrombopoietin would also be required to sustain normal megakaryocytopoiesis. This concept fits earlier data where thrombopoiesis persists at reduced rates in transfusion-induced thrombocytotic mice. Thus, in thrombocytopenic conditions, when thrombopoietin levels become elevated, an increased rate of megakaryocytopoiesis would be observed.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗